KRAS and neoplasm: While the enrollment criteria required patients to have RAS WT tumor tissue based on local assessment using a validated test, a small proportion of patients was found to have RAS mutations (6.0% with KRAS and 1.4% with NRAS mutations) according to the ctDNA test.